These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17403997)

  • 1. Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
    Lennerstrand J; Chu CK; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2078-84. PubMed ID: 17403997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
    Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
    Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.
    Jeffrey JL; Feng JY; Qi CC; Anderson KS; Furman PA
    J Biol Chem; 2003 May; 278(21):18971-9. PubMed ID: 12651859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
    White KL; Margot NA; Wrin T; Petropoulos CJ; Miller MD; Naeger LK
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3437-46. PubMed ID: 12384348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of dioxolane nucleosides against 3TC resistant M184V mutant HIV.
    Chong Y; Chu CK
    Antiviral Res; 2004 Jul; 63(1):7-13. PubMed ID: 15196815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.
    Lennerstrand J; Hertogs K; Stammers DK; Larder BA
    J Virol; 2001 Aug; 75(15):7202-5. PubMed ID: 11435603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
    Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
    Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.
    Feng JY; Myrick F; Selmi B; Deval J; Canard B; Borroto-Esoda K
    Antiviral Res; 2005 Jun; 66(2-3):153-8. PubMed ID: 15885814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl) thymine as an anti-HIV agent.
    Murakami E; Bao H; Basavapathruni A; Bailey CM; Du J; Steuer HM; Niu C; Whitaker T; Anderson KS; Otto MJ; Furman PA
    Antivir Chem Chemother; 2007; 18(2):83-92. PubMed ID: 17542153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism.
    Chu CK; Yadav V; Chong YH; Schinazi RF
    J Med Chem; 2005 Jun; 48(12):3949-52. PubMed ID: 15943470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Apr; 76(7):3248-56. PubMed ID: 11884549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.
    Quan Y; Gu Z; Li X; Liang C; Parniak MA; Wainberg MA
    J Mol Biol; 1998 Mar; 277(2):237-47. PubMed ID: 9514745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.
    Schneider A; Corona A; Spöring I; Jordan M; Buchholz B; Maccioni E; Di Santo R; Bodem J; Tramontano E; Wöhrl BM
    Nucleic Acids Res; 2016 Mar; 44(5):2310-22. PubMed ID: 26850643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2001 May; 75(10):4832-42. PubMed ID: 11312355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.